Published in Health Aff (Millwood) on January 08, 2008
Applications of two-part pricing in pharmaceutical markets. Health Aff (Millwood) (2008) 0.75
Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA (2001) 8.72
Employer drug benefit plans and spending on prescription drugs. JAMA (2002) 6.02
Pharmacy benefits and the use of drugs by the chronically ill. JAMA (2004) 5.56
The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s. Health Econ (2005) 3.61
Termination of Medi-Cal benefits. A follow-up study one year later. N Engl J Med (1986) 3.16
Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart (2002) 2.83
Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA (2004) 2.66
A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care (2001) 2.44
Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care (2006) 1.83
The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization. Med Care (1990) 1.61
Effect of tiered prescription copayments on the use of preferred brand medications. Med Care (2003) 1.58
The differential impact of copayment on drug use in a Medicaid population. Inquiry (1985) 1.45
The impact of increasing patient prescription drug cost sharing on therapeutic classes of drugs received and on the health status of elderly HMO members. Health Serv Res (1997) 1.27
Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care (2005) 1.22
Chip-NMR biosensor for detection and molecular analysis of cells. Nat Med (2008) 4.29
Prespecified falsification end points: can they validate true observational associations? JAMA (2013) 3.11
Trends in the earnings of male and female health care professionals in the United States, 1987 to 2010. JAMA Intern Med (2013) 2.97
Why physicians work when sick. Arch Intern Med (2012) 2.65
The benefits from giving makers of conventional 'small molecule' drugs longer exclusivity over clinical trial data. Health Aff (Millwood) (2011) 2.64
On average, physicians spend nearly 11 percent of their 40-year careers with an open, unresolved malpractice claim. Health Aff (Millwood) (2013) 2.26
Cost-effectiveness as a price control. Health Aff (Millwood) (2007) 2.11
The European Working Time Directive: an uncontrolled experiment in medical care and education. JAMA (2013) 2.10
Heterogeneity in action: the role of passive personalization in comparative effectiveness research. Health Econ (2013) 2.04
Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia. J Gen Intern Med (2012) 1.83
Out-of-pocket medication costs and use of medications and health care services among children with asthma. JAMA (2012) 1.83
Hospital spending and inpatient mortality: evidence from California: an observational study. Ann Intern Med (2011) 1.79
The growth of obesity and technological change. Econ Hum Biol (2009) 1.42
The value of specialty oncology drugs. Health Serv Res (2009) 1.24
Hospital value-based purchasing. J Hosp Med (2013) 1.21
An economic evaluation of the war on cancer. J Health Econ (2010) 1.13
The promise of health care cost containment. Health Aff (Millwood) (2007) 1.13
Outcomes of Basic Versus Advanced Life Support for Out-of-Hospital Medical Emergencies. Ann Intern Med (2015) 1.02
How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. Health Aff (Millwood) (2012) 1.01
The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. Health Aff (Millwood) (2012) 1.01
Medicare part D after 2 years. Am J Manag Care (2009) 0.99
The impact of comparative effectiveness research on health and health care spending. J Health Econ (2011) 0.98
Trends in the earnings of health care professionals in the United States, 1987-2010. JAMA (2012) 0.97
Spending and mortality in US acute care hospitals. Am J Manag Care (2013) 0.93
The pragmatist's guide to comparative effectiveness research. J Econ Perspect (2011) 0.92
Predicting new diagnoses of HIV infection using internet search engine data. Clin Infect Dis (2013) 0.91
Guidance for structuring team-based incentives in healthcare. Am J Manag Care (2013) 0.89
Defense costs of medical malpractice claims. N Engl J Med (2012) 0.89
Reducing Diagnostic Errors--Why Now? N Engl J Med (2015) 0.89
The economics of intense exercise. J Health Econ (2010) 0.87
The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). J Natl Cancer Inst (2015) 0.82
Effect of hospital use of oral nutritional supplementation on length of stay, hospital cost, and 30-day readmissions among Medicare patients with COPD. Chest (2015) 0.81
Postinterview communication between military residency applicants and training programs. Mil Med (2012) 0.81
Is the Food and Drug Administration safe and effective? J Econ Perspect (2008) 0.81
Polymerase translocation with respect to single-stranded nucleic acid: looping or wrapping of primer around a poly(A) polymerase. Structure (2009) 0.80
Can an acute pain service be cost-effective? Anesth Analg (2010) 0.79
Structure-based design of Aurora A & B inhibitors. J Comput Aided Mol Des (2008) 0.79
Clinical and economic outcomes of nutrition interventions across the continuum of care. Ann N Y Acad Sci (2014) 0.78
Falsification end points for observational studies--reply. JAMA (2013) 0.77
Dynamic cost-effectiveness of oncology drugs. Am J Manag Care (2012) 0.77
Balancing disease eradication with the emergence of multidrug-resistant HIV in test-and-treat policies. Clin Infect Dis (2013) 0.76
Response to Epstein's comment on "heterogeneity in action". Health Econ (2014) 0.75
Social desirability bias in self-rated presenteeism among resident physicians--reply. JAMA Intern Med (2013) 0.75
Behind-the-counter statins: a silver bullet for reducing costs and increasing access? Health Serv Res (2011) 0.75
Community-acquired pneumonia and proton pump inhibitors. J Gen Intern Med (2013) 0.75
Striking a balance on new technology. Cost-effectiveness analysis can help sort out emerging health care technologies, but what are the consequences for continued medical innovation? AHIP Cover (2006) 0.75
Duty hour reforms in Europe and the United States--reply. JAMA (2013) 0.75
Outcomes of Basic Versus Advanced Life Support for Out-of-Hospital Medical Emergencies. Ann Intern Med (2016) 0.75
The option value of innovative treatments in the context of chronic myeloid leukemia. Am J Manag Care (2012) 0.75
Chronic Opioid Use After Surgery: Implications for Perioperative Management in the Face of the Opioid Epidemic. Anesth Analg (2017) 0.75
Is Prehospital Advanced Life Support Harmful? Ann Intern Med (2016) 0.75
The Institute of Medicine report on the FDA: where is the science? Health Econ (2007) 0.75